Barclays PLC Has $344,000 Position in Nevro Corp. (NYSE:NVRO)

Barclays PLC trimmed its holdings in Nevro Corp. (NYSE:NVRO - Free Report) by 59.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 61,496 shares of the medical equipment provider's stock after selling 88,518 shares during the period. Barclays PLC owned about 0.16% of Nevro worth $344,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in NVRO. Rhumbline Advisers boosted its position in shares of Nevro by 5.0% during the second quarter. Rhumbline Advisers now owns 58,995 shares of the medical equipment provider's stock worth $497,000 after buying an additional 2,836 shares during the period. Blair William & Co. IL boosted its position in shares of Nevro by 13.9% during the second quarter. Blair William & Co. IL now owns 59,404 shares of the medical equipment provider's stock worth $500,000 after buying an additional 7,250 shares during the period. Canada Pension Plan Investment Board boosted its position in shares of Nevro by 345.8% during the second quarter. Canada Pension Plan Investment Board now owns 10,700 shares of the medical equipment provider's stock worth $90,000 after buying an additional 8,300 shares during the period. Hsbc Holdings PLC boosted its position in shares of Nevro by 21.4% during the second quarter. Hsbc Holdings PLC now owns 55,604 shares of the medical equipment provider's stock worth $459,000 after buying an additional 9,793 shares during the period. Finally, XTX Topco Ltd boosted its position in shares of Nevro by 84.6% during the second quarter. XTX Topco Ltd now owns 24,711 shares of the medical equipment provider's stock worth $208,000 after buying an additional 11,323 shares during the period. 95.52% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms recently issued reports on NVRO. Wells Fargo & Company dropped their target price on Nevro from $5.00 to $4.00 and set an "equal weight" rating on the stock in a report on Wednesday, December 11th. Royal Bank of Canada reiterated a "sector perform" rating and set a $7.00 target price on shares of Nevro in a report on Tuesday, November 12th. Morgan Stanley lowered Nevro from an "equal weight" rating to an "underweight" rating and dropped their target price for the stock from $9.00 to $4.00 in a report on Monday, December 2nd. StockNews.com upgraded Nevro from a "sell" rating to a "hold" rating in a report on Tuesday, November 19th. Finally, Truist Financial dropped their target price on Nevro from $7.00 to $4.70 and set a "hold" rating on the stock in a report on Wednesday, December 18th. Three investment analysts have rated the stock with a sell rating and eleven have assigned a hold rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $6.30.

Nevro Stock Performance

Shares of NYSE NVRO traded up $0.07 during trading hours on Monday, reaching $4.57. 388,855 shares of the stock were exchanged, compared to its average volume of 378,592. The firm has a market capitalization of $171.28 million, a price-to-earnings ratio of -2.42 and a beta of 0.86. The company has a debt-to-equity ratio of 0.67, a quick ratio of 3.76 and a current ratio of 5.02. Nevro Corp. has a 52 week low of $3.16 and a 52 week high of $19.47. The stock's fifty day simple moving average is $4.12 and its 200 day simple moving average is $5.57.

Nevro (NYSE:NVRO - Get Free Report) last announced its earnings results on Monday, November 11th. The medical equipment provider reported ($0.41) earnings per share for the quarter, topping analysts' consensus estimates of ($0.81) by $0.40. The company had revenue of $96.60 million for the quarter, compared to analyst estimates of $93.09 million. Nevro had a negative return on equity of 23.52% and a negative net margin of 16.54%. The firm's quarterly revenue was down 7.0% compared to the same quarter last year. During the same quarter last year, the company earned ($0.65) earnings per share. Sell-side analysts predict that Nevro Corp. will post -2.43 EPS for the current year.

Nevro Profile

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems.